Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NISCH | Q9Y2I1 | 11/20 | 0.43 |
| ▸ | ADRA2A | P08913 | 1/20 | 0.39 |
| ▸ | NAMPT | P43490 | 2/20 | 0.38 |
| ▸ | IDH1 | O75874 | 1/20 | 0.38 |
| ▸ | PDCD1 | Q15116 | 1/20 | 0.37 |
| ▸ | CD274 | Q9NZQ7 | 1/20 | 0.37 |
| ▸ | SSTR4 | P31391 | 1/20 | 0.37 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | RECQL | P46063 | 1/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16432908 | 0.79 | HTR2A (0.51) | NISCHADRA2A | |
| SCHEMBL10063594 | 0.71 | CCR1 (0.41) | NISCHNAMPTIDH1SSTR4 | |
| SCHEMBL16440326 | 0.70 | NISCH (0.47) | NISCHADRA2ANAMPTLMNA | |
| SCHEMBL17876772 | 0.70 | LMNA (0.45) | NISCHADRA2ANAMPTLMNARECQL | |
| SCHEMBL31298603 | 0.70 | KDM5A (0.44) | NAMPTSSTR4LMNA | |
| SCHEMBL9876833 | 0.69 | NAMPT (0.54) | NAMPTIDH1 | |
| SCHEMBL10457622 | 0.69 | GRM5 (0.43) | NAMPTIDH1SSTR4 | |
| SCHEMBL18056924 | 0.68 | NAMPT (0.40) | NAMPTIDH1 | |
| SCHEMBL1747623 | 0.68 | GSK3B (0.54) | NAMPTSSTR4LMNA | |
| SCHEMBL626956 | 0.68 | L3MBTL1 (0.54) | SSTR4 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CHEMOCENTRYX INC. (US) | 2013-07-18 | — | — | US | disclosed |
| US-8481545-B2 | 3-(imidazolyl)-pyrazolo[3,4-b] pyridines | CHEMOCENTRYX, INC. (US) | 2013-07-09 | — | — | US | disclosed |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2012-01-12 | — | — | US | disclosed |
| US-7960388-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2011-06-14 | — | — | US | disclosed |
| US-20100173911-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2010-07-08 | — | — | US | disclosed |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | CHEMOCENTRYX, INC. (US) | 2010-05-06 | — | — | US | disclosed |
| US-7629344-B2 | 3-(imidazolyl)-pyrazolo[3,4-b]pyridines | CHEMOCENTRYX, INC. (US) | 2009-12-08 | — | — | US | disclosed |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CHEMOCENTRYX, INC. (US) | 2008-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130184289-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-B]PYRIDINES | CCR1, CCR3, CCR4 | NISCH 2956/4885ADRA2A 785/4885NAMPT 1630/4885 |
| US-20080300257-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | NISCH 2956/4885ADRA2A 785/4885NAMPT 1630/4885 |
| US-20100113472-A1 | COMPOUNDS FOR THE TREATMENT OF OSTEOPOROSIS AND CANCERS | SOST, VDR, PTH1R | NISCH 512/4885ADRA2A 2565/4885NAMPT 116/4885 |
| US-20120010214-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | NISCH 2956/4885ADRA2A 785/4885NAMPT 1630/4885 |
| US-20100173911-A1 | 3-(IMIDAZOLYL)-PYRAZOLO[3,4-b]PYRIDINES | CCR1, CCR3, CCR4 | NISCH 2956/4885ADRA2A 785/4885NAMPT 1630/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.